Primary progressive multiple sclerosis to be treated with ocrelizumab: a mistaken case of cobalamin deficiency

BMJ Case Rep. 2019 May 14;12(5):e229080. doi: 10.1136/bcr-2018-229080.

Abstract

Cobalamin (vitamin B12) deficiency often manifests with neurologic symptoms and may rarely mimic multiple sclerosis (MS) among other neurological disorders. However, MRI changes associated with cobalamin deficiency are typically spinal predominant and distinct from MS-related changes. We report a case of a patient with cobalamin deficiency who was recommended by her primary neurologist to commence treatment with ocrelizumab, a potent anti-CD20 B-cell depleting monoclonal antibody, after being diagnosed with primary progressive MS. However, cervical spine MRI demonstrated changes classical of cobalamin deficiency including 'inverted V sign' signal hyperintensity and following parenteral cobalamin supplementation her neurological symptoms quickly and dramatically improved.

Keywords: multiple sclerosis; vitamins and supplements.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Cervical Cord / diagnostic imaging
  • Diagnostic Errors
  • Female
  • Humans
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / adverse effects
  • Immunologic Factors / therapeutic use
  • Multiple Sclerosis / diagnosis*
  • Multiple Sclerosis / drug therapy
  • Vitamin B 12 / administration & dosage*
  • Vitamin B 12 Deficiency / blood
  • Vitamin B 12 Deficiency / diagnosis*
  • Vitamin B 12 Deficiency / drug therapy*
  • Vitamin B Complex / administration & dosage*

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunologic Factors
  • Vitamin B Complex
  • ocrelizumab
  • Vitamin B 12